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Available online 27 February 2016The physicochemical properties of some contemporary drug candidates are moving towards higher molecular
weight, and coincidentally also higher lipophilicity in the quest for biological selectivity and speciﬁcity.
These physicochemical properties move the compounds towards beyond rule-of-5 (B-r-o-5) chemical
space and often result in lower water solubility. For such B-r-o-5 compounds non-traditional delivery strategies
(i.e. those other than conventional tablet and capsule formulations) typically are required to achieve adequate
exposure after oral administration. In this review, we present the current status of computational tools for
prediction of intestinal drug absorption, models for prediction of the most suitable formulation strategies for
B-r-o-5 compounds andmodels to obtain an enhanced understanding of the interplay between drug, formulation
and physiological environment. In silicomodels are able to identify the likelymolecular basis for low solubility in
physiologically relevant ﬂuids such as gastric and intestinal ﬂuids. With this baseline information, a formulation
scientist can, at an early stage, evaluate different orally administered, enabling formulation strategies. Recent
computational models have emerged that predict glass-forming ability and crystallisation tendency and there-
fore the potential utility of amorphous solid dispersion formulations. Further, computational models of loading
capacity in lipids, and therefore the potential for formulation as a lipid-based formulation, are now available.
Whilst such tools are useful for rapid identiﬁcation of suitable formulation strategies, they do not reveal drug
localisation andmolecular interaction patterns between drug and excipients. For the latter, Molecular Dynamics
simulations provide an insight into the interplay between drug, formulation and intestinal ﬂuid. These different
computational approaches are reviewed. Additionally, we analyse the molecular requirements of different tar-
gets, since these can provide an early signal that enabling formulation strategies will be required. Based on the
analysis we conclude that computational biopharmaceutical proﬁling can be used to identify where non-
conventional gateways, such as prediction of ‘formulate-ability’ during lead optimisation and early development
stages, are important and may ultimately increase the number of orally tractable contemporary targets.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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An increasingnumber of discovery biology frameworks appear to re-
quire highly lipophilic drug candidates to attain reasonable potency and
selectivity. Such targets include those within lipid metabolic pathways
where the natural ligands are lipids [1,2], targets within neurotransmit-
ter pathways where the endogenous agonists are highly lipophilic [3],
and anatomical targets where access to them requires lipid transport
pathways [4], and/or partitioning into deep intracellular or nuclear tar-
gets [5]. Typically, highly lipophilic compounds exhibit poor solubility in
water, and it is estimated that 40% to 70% of current drug candidates
have sufﬁciently poor aqueous solubility that complete absorption
from the intestine is compromised [6,7]. As oral dosage forms are the
most convenient for patients, new medicines usually include oral
delivery as part of their target product proﬁle. This is in particular true
when the disease is chronic and requires long term, or even life-long,
treatment.
Computational tools based on calculations frommolecular structure
are available to facilitate the rational development of hits, leads
and drug candidates with favourable physicochemical proﬁles for oral
absorption [8–11]. These tools assist medicinal chemists in designing
molecules with acceptable absorption, distribution, metabolism, elimi-
nation and toxicity (ADMET) properties. Nevertheless, the current
drug discovery and clinical pipeline is still dominated by small mole-
cules that often have problems with absorption and adequate drug
exposure. Indeed, the trend is towards larger molecular weight and
more lipophilic drug molecules that are even less well predisposed to
good oral absorption. This trend has been attributed to the intrinsic bi-
ology of the target [5,12–14], the nature of the chemistry used to devel-
op libraries [12,15,16], and organisational factors such as screening
mechanisms, decision gates, experience and historical libraries [16,17].
Lipophilic ligands pose challenges at all ADMET levels. A recent anal-
ysis of the attrition rate of drug candidates highlights the need to better
understand non-clinical toxicity, i.e. toxicity identiﬁed before clinical
trials. Of 356 compounds from four major pharmaceutical companies,
non-clinical toxicity was responsible for 59% of compound attrition. In
contrast, only 2.8% of the pre-clinical attrition of candidate drugs was
due to pharmacokinetics (PK), bioavailability and formulation. This
number increases, however, after moving into the clinic i.e., Phase I–III
clinical studies. Clinical safety is still responsible for the highest fraction
of attrition (25%) in Phase I, but PK, bioavailability and formulation
account for 17% of the attritions [13]. Failures in obtaining good oral
exposure – stemming from poor formulation performance, absorption
and other PK related factors – tend to be identiﬁed late, with costly
termination of the projects as a result.
Targets are broadly evaluated for their ‘druggability’, a term general-
ly deﬁned as the likelihood of being able to functionally modulate a
target through interaction with a small molecule or biological ligand
[18–20]. However, methods that more speciﬁcally determine whether
the target is tractable from the perspective of a (readily) orally delivered
drug product are also required but are not currently explicitly available.
In this review we present the use of in silico tools for prediction of ab-
sorption barriers to orally administered drugs with focus on solubility
in intestinal ﬂuids (S) and permeability (Papp). For those compounds
where solubility is the main limiting factor, we present recent in silico
developments for assessment of the molecular basis for this poorsolubility; this information can then guide the selection of formulation
strategy. We also present a computational approach that combines bio-
pharmaceutical performance of the active pharmaceutical ingredient
(API) with its likely ‘formulate-ability’. The concept underpinning this
approach is that such an analysis may make it possible to identify
drug targets for which traditional delivery technologies are likely to re-
sult in good absorption. More interestingly, it will ﬂag targets with
future needs for non-standard, enabling formulations to provide accept-
able exposure after oral administration of e.g., highly lipophilic, poorly
water-soluble drug candidates. There is a diverse range of enabling for-
mulation strategies that can be employed; herein we present, in detail,
computational approaches to predict i) solid-state transformations to
indicate the potential use of the amorphous form to improve drug
absorption and ii) solubility in non-aqueous vehicles, to indicate the
potential utility of lipid-based formulations (LBFs).
2. Understanding the target biology
To develop target-relevant decision gates to guide lead optimisation
(also discussed in Section 7) acknowledgement of the inﬂuence of the
inherent biology of the target on druggability is increasingly important
[5,21]. Several tools that identify target druggability have been pro-
posed [18–20,22]. These are mainly suggested as a means to identify
new druggable binding sites, which are typically deﬁned as chemical
target regions in which the binding pocket may be occupied by com-
pounds that comply with the rule-of-5. Although this approach may
change the target biology used in certain therapeutic areas, and result
in the development of new compound libraries with more drug-like
properties, other targets will likely remain in the ‘non-druggable’, be-
yond rule-of-5 (B-r-o-5), chemical space. This space is typically occu-
pied by highly lipophilic ligands to e.g. intracellular targets such as
nuclear receptors including the Farnesoid X Receptor (FXR) and retinoic
acid receptor (RAR), or larger, hydrophilic ligands within the chemical
space occupied by e.g. peptides, antibiotics and macrocycles. The latter
are described in detail by Matsson et al. [23].
The druggability of the target can be identiﬁed computationally by
deﬁning the pocket with geometric criteria and using molecular de-
scriptors [22]. If the analysis shows the pocket to be a lipophilic non-
druggable binding site, this may be a ‘stop, or at least a caution’ gate
way in the target identiﬁcation process provided that other, more
druggable, speciﬁc targets are available for the disease area under eval-
uation. However, this type of analysis can also be used to identify
druggable, B-r-o-5 targets, i.e. those that need macrocycles or highly li-
pophilic ligands to become activated. In a recent paper, a computational
analogue of NMR measurements, in which the algorithm is based on
the biophysics of binding rather than empirical parametrisation,
was successfully identifying druggable and non-druggable targets in
the B-r-o-5 space [24].
The following sections focus on absorption enhancement for B-r-o-5
ligands. Ligands in the hydrophilic B-r-o-5 chemical space are typically
water soluble but permeability-limited in their absorption; Matsson
et al. and Krämer et al. give a state-of-the-art analysis of this chemical
domain [23,25]. Our focus is on ligands occupying the highly lipophilic
B-r-o-5 chemical space; compounds that tend to be highly permeable
but with solubility (or dissolution)-limited absorption. Although the
analysis focuses on absorption, it needs to be emphasised that to
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ADMET properties need to receive the same level of acknowledgement
as pharmacological potency in the early stages of the research
programme.
3. Computational models based on quantitative structure property
relationships (QSPR)
A number of different computational tools are available to better
predict and understand properties involved in drug absorption from
the gastrointestinal tract (GIT). Statistical models based on regression
analysis of a number of descriptors and the response of interest (e.g. sol-
ubility, permeability, interactions with transport proteins) have gained
in popularity, partly due to their ease to use and the speed by which
the predictions are performed. These multivariate data analysis models
are inspired by quantitative structure–activity relationships (QSAR)
used in medicinal chemistry to explore potency of ligand series to esti-
mate the activity of new analogues. QSAR as a phenomenon appeared in
the early 1970s and typically was based on the correlation between a
single property (univariate) and the response in an activity screen.
Later more complex models for activity was developed; these were
based on several molecular properties (multivariate) to be more
predictive. Translating QSAR to prediction of processes importance for
e.g. drug absorption and distribution resulted in the term QSPR where
the P stands for Property. Mayer and van de Waterbeemd reviewed
the early work in the QSAR and QSPR ﬁeld in 1985 [26]; they already
then concluded that quantitative approaches of pharmacokinetics and
toxicity are of considerable interest. However, there also a number of
risks with relying too much on QSPR approaches, some of which are
described here.
A factor signiﬁcantly inﬂuencing the accuracy and applicability do-
main of the model is the dataset used. The models cannot be better
than the quality of the experimental data that is used, and great efforts
are put into establishing large enough datasets to allowmodelling but at
the same time producing experimental data of high quality. The
applicability domain is within the chemical space that has been used
for training the model. To simplify, the training set used for the model
development (i.e. the compounds that have been used to extract de-
scriptors that correlate to the response) can be viewed as the ‘standard
curve’ used for the assessment (prediction); the validity of themodel is
within this domain. Hence, the model can be used to predict new
compounds within this chemical domain and should not be used for
compounds sitting outside this space. Typically compounds that are sit-
ting outside the validated chemical space are identiﬁed for the user by
e.g. ﬂagging that the compound is not described well by the training
set. Ifworkingwithin a speciﬁc chemical space it is often better to devel-
op local models, i.e. models that are built around a particular ligand se-
ries or chemistry, to obtain good predictions of new compounds within
this chemical space. If instead themodel is supposed to be of general ap-
plicability and allow prediction of any new compound, global models
based on large, structurally diverse drug-like compounds should be
used [27].
Recently, Palmer and Mitchell provided data that indicated that the
(poor) performance of solubility models is not related to the varying
data quality of different training sets used, rather it is related to the de-
ﬁciency in the descriptors used [28]. QSPR models are so called ligand-
based models where information extracted from the structure of the
compounds is related to the response through a statistical model. A
number of theoretical approaches and algorithms are available that
can provide such information and typically the information is presented
as differentmolecular descriptors. Some of these are rather easily calcu-
lated and interpreted, e.g. the number of double bonds and the number
of rotatable bonds and typically the values of these do not vary between
different methodological approaches. However, molecular descriptors
heavily dependent on conformational changes, e.g. intramolecular hy-
drogen bonds as described by Matsson et al. [23] and Krämer et al.[25], will be highly dependent on the 3D conformer(s) used for calcula-
tions. To reduce this effect dynamic descriptors can be calculated, a
strategy that has been used when calculating molecular surface area
such as the polar surface area (PSA) [29–31]. The dynamic PSA is calcu-
lated according to a Boltzmann distribution where every low energy
conformer is weighted for its probability of existence. If instead the stat-
ic PSA is used, the PSA is calculated on the conformer at the global ener-
gy minimum. For both these measures a conformational search has to
be performed to obtain the description of the surface area. The calcula-
tion of PSA was simpliﬁed by Ertl and colleagues by making use of
tabulated surface contributions of polar fragments [32]. Through this
approach they established the rapidly calculated topological PSA
(often abbreviated TPSA) which today is the commonly used PSA de-
scriptor. The TPSA is 2–3 orders of magnitude faster to calculate but
still highly correlated to the 3D PSA for molecules with a molecular
weight of 100–800 (R of 0.99). However, the TPSA will not allow for
identiﬁcation of importance of conformational changes on the polarity
of the compounds and hence, for compounds where conformational
ﬂexibility will assist in changing hydrogen bond capacity, the TPSA
and dynamic PSA will likely differ signiﬁcantly. In addition, the impor-
tance of which conformer that is used for calculation is greater for larger
molecules such as macromolecules [33]. This discussion on PSA serves
to illustrate howdifferent approaches and algorithmsmay produce sim-
ilar (or dissimilar) values when used to calculate molecular descriptors.
The statistical model that is used will further inﬂuence the accuracy
of the prediction. The most commonly used methods for prediction of
absorption related properties (solubility, permeability, transporter in-
teractions) are different linear and non-linear methods such as partial
least squares projection to latent structures (PLS), support vector re-
gression/machines (SVR/SVM), random forest (RF) and artiﬁcial neural
network (ANN); the interested reader is referred to articles that provide
details on these methods and their use for QSPR [34,35]. Sometimes
these models are used in combination in so called consensus models
to obtain more robust predictions. Common for all the models is that
they extract descriptors that are correlated to the response parameter.
To certify that the extracted descriptors truly are correlated to the re-
sponse (and not only a result of e.g. a biased dataset) several different
measures are taken and typically resampling measures are used to in-
vestigate model robustness and signiﬁcance of descriptors. Examples
of such are the cross-validated R2 (Q2), boot strapping and permutation
tests. Q2 is a statistical measure of how well the model performs when
subsets of the training set are excluded from the model generation. R2
and Q2 are similar if not heavily biased towards particular compounds
in the dataset. The signiﬁcance of the descriptors included in the ﬁnal
model should then be tested by e.g. performing permutation tests
(randomisation of the data set) or bootstrapping (resampling the
dataset). Finally, the model should be validated with an external test
set, i.e. a dataset that has not been included during the model develop-
ment. If all thesemeasures are good, i.e. themodel is proven not heavily
weighted by particular compounds and provides good prediction of the
external dataset, the model is validated and can be released to use. By
using thisworkﬂowand taking these precautions the risk for identifying
factors that are not truly related to the response are signiﬁcantly re-
duced. However, it is important that model developers and users of
computational models are aware of the inﬂuence of the quality of the
training set and descriptors used for the model development, as well
as the impact the statistical model has, on the ﬁnal predictions.
4. Prediction of solubility
4.1. Intrinsic solubility
Intrinsic solubility is the thermodynamic solubility of the drug at a
pH where the compound is completely non-ionised. It is determined
after equilibrium has been established between the solid (stable poly-
morph) and the dissolved form. Computational models that predict
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tivariate data analysis, e.g. methods such as PLS, ANN, SVR and RF. These
methods provide quantitative output. The accuracy of the prediction is
around 0.5 up to 1 log10 unit, i.e. a predicted solubility value can be ex-
pected to be up to 3–10 times different from that experimentally deter-
mined [27,28]. Molecular descriptors that appear to be important for
intrinsic solubility are lipophilicity, non-polar surface area, molecular
ﬂexibility and aromaticity/π–π interactions [27,36,37].
Thermodynamically, solubility is a result of the ease with which a
molecule dissociate from its crystal unit cell and the ease with which
it is hydrated once in solution. This is clearly visualised in the General
Solubility Equation (GSE). This equation describes the stability of the
crystal lattice via the melting point (Tm) and the ease with which a
compound is hydrated by the partition coefﬁcient between octanol
and water (logP) (Fig. 1) [38]. Tm is commonly used to identify com-
pounds where solubility is limited by solid-state properties. These com-
pounds are sometimes colloquially referred to as “brick dust”molecules
to visualise a densely packed, tightly “glued” solid structure [37,39].
In contrast, logP identiﬁes compounds having a solvation-limited
solubility. These are sometimes colloquially referred to as “grease ball”
molecules because of their unfavourable interactions with bulk water
[36,40]. The somewhat lower accuracy of solubilitymodels as compared
to other response data such as permeability and lipophilicity has been
attributed, at least in part, to the inﬂuence of solid state properties on
solubility. It is well-known that it is not yet possible to quantitatively
predict the strength of the crystal lattice by computational means and
hence, the solid-state contribution to the solubility is not captured
well by in silico models. However, successful MD simulations of the
crystal lattice (without need of experimental input) of organic, small
molecules (n-alkylamides) were recently published [41], but crystal
structure of molecules that are larger, ﬂexible and with several polar
functions (typical drug-like features) has been proven more difﬁcult
to predict [42]. When successful, these simulations hold great potential
to improve predictions of phenomena dependent on the solid state (e.g.
dissolution, solubility, supersaturation), since they are ab initio calcula-
tions and hence, can be used to predict the crystal structure of any new
drug.
Attempts to predict Tm have been made, and computationally it is
possible to predictwhether a compound is likely to be low, intermediate
or high melting using classiﬁcation models with cut-off values of e.g.
120 and 180 °C [43]. However, in absolute numbers, melting pointFig. 1. The thermodynamic principles of dissolution. The drugmolecule needs to dissociate from
to incorporate the drug molecule. Both these processes demand energy. The molecule can th
properties can be used to indicate which process is likely to limit solubility. For dissociation fr
N200 °C are at greatest risk of solid-state limitations (i.e. intermolecular force) to solubi
lipophilicity are poorly hydrated and compounds with a logD N 3 are at risk for having a solv
impact of melting point (Tm) and lipophilicity (in form of logPoct) on solubility is captured bycannot be expected to be predicted with accuracy greater than 30 °C
for compounds in general [44], and up to 40 °C for drug-like compounds
[43]. These inaccuracies should be kept in perspective; APIs that are
solids at room temperature typically have Tms in the range of ~60–
350 °C (a rather narrow interval in absolute number), with most of
them melting between ~100 and 250 °C. A recent study based on in
silico solid state perturbation and the 2D molecular structure, presents
an interesting computational methodology to study the impact of the
solid state on the ﬁnal solubility [39]. Future development of this meth-
od and methodologies based on molecular and quantum mechanics
have the potential to contribute to more accurate predictions of crystal
lattice properties and their inﬂuence on other responses such as
dissolution rate and solubility.
4.2. Solubility in intestinal ﬂuids
The intrinsic solubility value is not a physiologically relevant
measure for many ionisable compounds; rather it should be seen as a
physicochemical ﬁngerprint of the molecule. After oral administration,
a drug will be exposed to a wide range in pH. In the fasted state, the
pH of the stomach is acidic (pH of 1.7–3.3; median of 2.5) whereas it
is neutral or slightly basic (6.5–7.8; median of 6.9) in the distal part of
jejunum [45]. The pH thereafter remains at a high level, with an average
pH of 8.1 and 7.8 reported for the fasted distal part of the ileum and
colon, respectively [46,47]. In addition to the pH-gradient, the secretion
of bile in the duodenum results in the generation of lipoidal
nanoaggregates, e.g. mixedmicelles and vesicles composed of phospho-
lipids and bile salts, that are naturally present in the intestinal ﬂuid. The
combination of changes to pH and the presence of nanoaggregates with
high solubilising capacity, signiﬁcantly inﬂuences the ﬁnal solubility of
drugs in the intestinal ﬂuid. The solubility therefore differs between in-
dividuals and is dependent on food composition and prandial state [48].
As a result, solubility prediction in the intestinal ﬂuids is complex.
The simplest strategy is to use in silico models to predict intrinsic
solubility and pKa, and then to put these values into the Hendersson–
Hasselbalch equation. More recently in silico models that target predic-
tion of solubility in fasted human intestinal ﬂuid (HIF), or in biorelevant
dissolution medium mimicking this ﬂuid, have appeared [49]. With
chemical information calculated from the molecular structure alone
these models can predict the solubility in these complex body ﬂuids.
Fagerberg et al. reported root mean square error (RMSE) for predictionsits solid crystal lattice and the solvent (e.g. water) needs to open up a cavity large enough
ereafter become hydrated, a process that releases energy. For each of these steps drug
om the solid state melting point is typically used. Compounds displaying a melting point
lity; these are sometimes referred to as brick dust molecules. Compounds with high
ation limited solubility; such compounds are sometimes referred to as grease balls. The
the General Solubility Equation established by Yalkowsky and coworkers [38].
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tion set, respectively. Similar accuracy has been obtained for prediction
of drug solubility in fasted state simulated intestinal ﬂuid (FaSSIF). To
date, there are two different datasets and models openly available to
the scientiﬁc community for prediction of drug solubility in FaSSIF.
One of these is a recently published PLSmodel based on 56 compounds
used for training the model and 30 compounds for validation [49]. This
model had an RMSE of 0.77 (log10 units) for the validation set. The other
model is based on ANNand is available in the software ADMET Predictor
[50]. Thismodel was developed based on 141 compounds and validated
using 14 compounds resulting in an RMSE of 0.48 log10 units for the
validation set.
The PLS models published by Fagerberg et al. were based on struc-
turally diverse datasets. For these datasets,molecular size and aromatic-
ity were found to be two of the most important limiting molecular
descriptors for solubility in aspirated and simulated intestinal ﬂuids
[49]. The datasets used were biased towards lipophilic compounds
since these are known to be signiﬁcantly solubilised in the colloidal
structures of the intestinal ﬂuid and therefore merit experimental de-
termination in e.g. aspirated human intestinal ﬂuid. The logDpH 6.5 of
the compounds used to train the HIF and FaSSIF models was in the
range of 0.3–6.0 and hence, hydrophilic compounds were not included
in the analysis. The size factor was interpreted as reﬂecting the fact
that larger molecules require larger cavities in the solvent to hydrate
the molecule. However, it is well-known that as molecular size in-
creases, lipophilicity also usually increases, and hence, size descriptors
may also indirectly carry information from other variables, such as lipo-
philicity, and therefore include their impact on solubility. Similarly, aro-
maticity carries information about lipophilicity, but is also important in
determining the likelihood of formation of a stable and densely packed
crystal lattice [37,51,52]. For example, interconnected aromatic rings in
a structure usually raise the Tm. Once such highly interconnected struc-
tures are in solution, the aromatic features cannot be shielded from the
water by folding. This is unlike the situation for highly ﬂexible, aliphatic
structures which can fold to minimise the surface area exposed to
water. The models also showed that the potential to form hydrogen
bonds is positive for solubility. This is intuitive since functional groups
that can form hydrogen bonds also facilitate direct interaction with
the water molecules. Another, recent analysis of solubility data mea-
sured in HIF and FaSSIF revealed that compounds with logD N 3 should
be evaluated for intestinal solubility using a biorelevant dissolutionme-
dium with lipids present [53]. Above this value, the solubility in FaSSIF
or fed state simulated intestinal ﬂuid (FeSSIF) is often 10 to 100-fold
higher than that measured in a pure buffer without phospholipids
and bile salt. However, even at lower logD values, there can be a 2 to
4-fold higher solubility in these media compared to pure buffers.
5. Molecular determinants of solubility: can you see a grease ball
(or brick dust) coming?
The molecular features determining solid-state limited or solvation-
limited solubility have been studied by using a range of poorly soluble
compounds [36,37,40,54]. Solvation-limited molecules, i.e. “grease
balls”, are relatively large, ﬂexible and lipophilic (logD N 3) [36]; many
of them are on the border of, or inside, the B-r-o-5 chemical space. An
analysis of dosage forms employed for such compounds reveals the re-
quirement for excipients that facilitate dissolution and solubilisation
(e.g. disintegrants, suspending agents, wetting agents, solubilisers) in
order to developwell-functioning oral dosage forms [36]. Hence, poorly
soluble, solvation-limited, compounds are possible to bring to the
market, albeit after extensive formulation development. Other studies
have focused on solid-state limited compounds. According to the GSE,
these compounds are usually found in the lower lipophilicity range
(logP-valuesb2) (since higher log P compounds are likely to be
solvation limited). Indeed, based on a dataset of compounds with low
lipophilicity (logP of ~2) but up to 1000-fold differences in solubility,strong correlations were observed between solubility and Tm and en-
thalpy of fusion (Hfus) (R of 0.84 for both properties) [37,55]. Further
analysis of these compounds showed that, in agreement with previous
Tmanalyses, solid-state limited compoundswere often small molecules
with a large degree of planarity (therefore favouring molecular pack-
ing). Compounds with reasonable solubility in this data set had ﬂexible
side chains and therefore greater conﬁgurational entropy. Hence, the
molecular determinants of “grease ball” and “brick dust” molecules
can be clearly differentiated. The latter are smaller, rigid and typically
positioned inside the rule-of-5 chemical space, whereas “grease balls”
are larger, ﬂexible and lipophilic and often on the border of, or inside,
the B-r-o-5 chemical space. Intermediates of these extremes are also
present; these are highly lipophilic, highly aromatic structures hindered
in their solubility by both their solid state properties and poor hydra-
tion. Examples of such structures are ligands of the RAR (e.g. acitretin
with a logP of 5.6 and Tm of 221 °C) and ligands of hormone receptors
such as the thyroid hormone receptors (e.g. levothyroxine with a logP
of 4.6 and Tm of 235 °C) [56].
Whilst such structures may be highly potent in biochemical screens,
they are extremely challenging molecules to translate to functional
medicines. High lipophilicity as a result of aromatic structures such as
benzene rings, not only reduces solubility, but is also known to increase
metabolic vulnerability. Further it increases the likelihood of non-
speciﬁc hydrophobic interactions with off-target receptors (receptor
promiscuity) and therefore the potential for toxicity [57–59]. Such
structures are difﬁcult to formulate since several approaches must be
used in concert to overcome both solid-state and solvation limitations.
Nonetheless, the two examples above, acitretin and levothyroxine,
have been successfully developed as rather conventional oral dosage
forms mainly taking use of disintegrants. Levothyroxine has a dose in
the lower μg range and hence, the required solubility (for complete dis-
solution) in the intestinal ﬂuid for this compound is only 0.8 μM—most
likely explaining the relatively straightforward formulation. In contrast,
according to the Swedish Physician's Desk Reference acitretin has a 500-
fold higher dose than levothyroxine andmight therefore be expected to
provide a much greater challenge. The product labelling for acitretin
suggests that it should be takenwith ameal since the absorption is dou-
bled in the presence of food or milk. Milk is a natural emulsion of fat
with a complex digestion pattern and forms solubilising lipodal
nanoaggregates of different liquid crystalline forms during lipolysis
[60]. In the case of acitretin food is providing the additional
solubilisation capacity required to support absorption. The bioavailabil-
ity of acitretin is 60% under fed conditions, when high amounts of natu-
rally available lipids are present, but still it is highly variable (36–95%)
[61].
6. Prediction of permeability
The permeability of compounds is positively related to lipophilicity
and negatively related to hydrogen bond capacity and molecular size
[29,30,62]. Hence, membrane permeability, resulting from passive dif-
fusion across the lipoidal membrane, is typically high and absorption
is not permeability-limited for compounds belonging to the lipophilic,
B-r-o-5 chemical space. In contrast, highly polar and larger molecules
commonly exhibit permeability-limited absorption. The reader is
referred to the recent review on macromolecules by Matsson et al. for
further details [23]. For lipophilic drugs, whilst intrinsic membrane per-
meability is often high, other cellularmechanismsmay play a role in the
transport rate and the ease with which highly lipophilic compounds
cross cells and, e.g., are absorbed from the intestine. Entrapment in
the membrane, non-speciﬁc binding to intracellular proteins, as well
as speciﬁc binding to membrane-bound transport proteins responsible
for efﬂux, may become signiﬁcant determinants of the rate and extent
of the cellular transport [63–65].
The complexity of cellular transport is not considered in traditional
in silico models of cell permeability. Instead datasets obtained from
Box 2
Development of the computational biopharmaceutical profiling (CBP)
tool to assess absorption and signal need for enabling formulations.
Molecular descriptors andmultivariate data analysis: All molecular
structures were produced as sdfs in ChemDraw Ultra 11.0
(Cambridge Soft, UK) and submitted for calculation of molecular
descriptors by the software DragonX 1.4 (Talete, Italy). Physio-
logically relevant propertieswere predictedwith ADMET Predictor
(Simulations Plus, CA), e.g. permeability, pH-adjusted lipophilicity
and solubility (pH 6.5.and 7.4), and solubility in fasted state sim-
ulated gastric fluid (FaSSGF) and fasted and fed state intestinal
fluids (FaSSIF and FeSSIF, respectively). These analyses were
performed at the compound level and the target level, the latter be-
ing used to identify the importance of target biology on the bio-
pharmaceutical profile of the ligands.
A modified biopharmaceutics classification system (BCS) applica-
ble to the drug discovery setting: The solubility criterion usedwas
the maximum concentration (solubility) that could be achieved in
the intestinal fluid (pH 6.5) rather than the likelihood of complete
dissolution of a dose at the pH interval 1–6.8which is the criterion
used by e.g., the European Medical Agency (EMA) and the World
Health Organization (WHO). These adjustments were performed
to make the framework applicable to the discovery setting where
the dose is not yet established and to give higher priority to the in-
testinal compartment where the majority of the absorption takes
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designed to delineate the passive diffusion component are used for
development of computational models [29,33,66]. Other factors of im-
portance for absorption, such as active transport and inhibition thereof,
are treated in separate computational models [67]. The permeability
values obtained from cell-based models have been shown to correlate
with the effective permeability (Peff) in humans [68,69]. These cell-
based assays allow rapid determination of permeability at a relatively
low cost and are therefore used as surrogates for in vivo determinations.
The availability of in vitro cell-lines and development of high through-
put permeability methods, make it feasible to screen enough com-
pounds that the resulting datasets are of sufﬁcient size to extract
chemical information of importance for cell permeability. In addition
to the cell-based permeability datasets, Peff data from human perfusion
studies have been used for permeability modelling. An update of avail-
able Peff data of chemically structurally diverse compounds is provided
by Dahlgren et al. [70]
Similar computational model strategies and multivariate tools
(i.e. PLS, ANN, SVR, RF) are used for prediction of permeability as for sol-
ubility. A number of models are commercially available, see e.g. the re-
viewbyNorinder and Bergstrom [34]. The accuracy of in silicomodels is
0.39–1.43 log10 units for the validation test sets [71]. In silico models to
predict Peff have also been developed; these typically have similar
accuracy as the cell-based models [50,72]. However, it should be
noted that the Peff models are usually evaluated using fewer test
compounds (generally nb10), since the available dataset is small.place. In addition, intermediate classeswere introduced to provide
a more transparent system with regard to the analysis of formula-
tion dependence during the early development stages. Another
reason for including an intermediate class was to increase the reli-
ability of the predictions of high and low permeability/solubility by
having this class as separator. The following cut-off values were
applied: High effective permeability (Peff) N 1.0 × 10
−4 cm/s,
Low Peff b 0.2× 10
−4 cm/s, and Intermediate permeability in be-
tween these values. High solubility N 200 μM, Low
solubility b 50 μM, Intermediate solubility in between these7. Computational biopharmaceutical proﬁling
A tool for computational biopharmaceutical proﬁling (CBP) was
recently developed in-house to explore the ‘required’ lipophilicity for
particular targets. The hypothesis was that such a tool could be used
to provide an early signal of the need of an enabling formulation strate-
gy for particular biologies (Box 1). The CBP is based on in silico models
for predictions of solubility in FaSSIF and FeSSIF, and Peff (Box 2). FromBox 1
Dataset used for computational biopharmaceutical profiling.
Themolecular requirements of the targetswere analysed based on
reviews of ligand patents [73,138–165]. The therapeutic areas
coveredwere: addiction, allergy, arthritis, bacterial and viral infec-
tions, cancer, cardiovascular diseases, diabetes, epilepsy, inflam-
mation, liver diseases, CNS-related diseases (anxiety, Alzheimer's
disease, cognition impairment, depression, Parkinson's disease
and schizophrenia), immunological disorders,metabolic syndrome
(lipid metabolism, carbohydrate metabolism, obesity), pain, pul-
monary diseases and stroke. The final data set consisted of
1620 compounds and for these ligands datawere available to per-
form target-specific analysis for: adenosine receptors A1 to 3
(A1–3), anaplastic lymphoma kinase (ALK), bacterial topoisomer-
ase (BT) 2 and 4, cannabinoid receptors (CB) 1 and 2, cholesteryl
ester transfer protein (CETP), farnesoidX receptor (FXR), FMS-like
tyrosine kinase 3 (FLT3), GABAB, glucocorticoid receptor (GR),
histamine 3 receptor (H3R), HIV chemokine receptors (CCR5,
CXCR4), HIV-1 non-nucleoside reverse transcriptase (NNRT),
17β-hydroxysteroid dehydrogenases (17β-HSD3), 5-hydroxy-
tryptamine subtype 2c (5-HT2), 5-hydroxytryptamine subtype 6
(5-HT6), melatonin receptors (MT) 1 and 2, neurokinin receptors
(NK) 1 and 3, platelet derived growth factor (PDGF), prostaglandin
D2 receptor (CRTH2), protease activated receptor 1 (PAR),
retinoic acid receptor (RAR), γ-secretase (Aβ42), soluble epoxide
hydrolase (sEH), type T calcium channels (TTCC and Cav3.1) and
viral envelope glycoprotein 120 (gp120).
values. For an ‘average’ oral drug with a molecular weight of
350, and an available dissolution volume of 250 ml (based on
the volume of a glass of water), this corresponds to doses in the
lower milligrame scale. The 50 μM solubility value, in conjunction
with a 250ml dissolution volume, suggests that a dose of 4.4 mg
can be dissolved. Assuming a 200 μM solubility limit a dose of up
to 17.5mgmay be soluble. Hence, these cut-off values do not ex-
aggerate the impact that solubility will have on the absorption,
rather the reverse.1620 discovery compounds in the patent literature itwas possible to ex-
tract the molecular requirements of ligands for 32 different targets. In
general, the ligands investigated were clustered in the oral drug-like
chemical space, but in the region where poorly soluble, solvation limit-
ed compounds are positioned, i.e. the compounds examinedwere large-
ly poorly water-soluble compounds resulting from poor hydration [36].
In the following sections the use of CBP to prospectively indicate the
need for enabling formulations is described.7.1. Lipophilicity of targets
Whilst the properties of the complete dataset were generally consis-
tent with previous reports, the drug candidates to different target biol-
ogies had signiﬁcantly different lipophilicity proﬁles (Fig. 2). Human
targets with ligands having logPs of 2–3 (typically suggested to
be ideal for good absorption) included adenosine receptors A1 to 3
(A1–3), HIV chemokine receptor (CXCR4), 5-hydroxytryptamine sub-
type 2c (5-HT2), andmelatonin receptors (MT) 1 and 2. Of all the ligands
Fig. 2. Target speciﬁc lipophilicity proﬁles obtained through calculation of the partition coefﬁcient between octanol andwater for ligand series for each receptor. Upper panel: Proﬁle based
on logP, i.e. the partition coefﬁcient determined in pH-adjusted water such that only the neutral species is present. Mid panel: Proﬁle calculated at pH 6.5 to predict the lipophilicity
(logDpH 6.5) in the small intestine. Lower panel: Proﬁle calculated at pH 7.4 to predict the lipophilicity (logDpH 7.4) in the systemic circulation. Abbreviations of targets are provided in
Box 1. For function the following abbreviations are used: Agonist (ag), inhibitor (i), antagonist (an), modulator (m).
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mean logP of less than 2. Several targets (e.g., glucocorticoid receptor
(GR), cannabinoid (CB) 2, 17β-hydroxysteroid dehydrogenases
(17β-HSD3), γ-secretase (Aβ42), anaplastic lymphoma kinase (ALK))
had ligands in close proximity to the rule-of-5 cut off for lipophilicity
(Fig. 2). Perhaps most importantly, the analysis reveals that for some
targets the compound libraries had mean logP ≥ 5, i.e. the mean value
of ligands to each of these targets is outside of traditional r-o-5 space
with respect to lipophilicity. These targets were: CB 1, cholesterylester transfer protein (CETP), farnesoid X receptor (FXR), neurokinin
receptors (NK) 1 to 3, protease activated receptor (PAR) 1, and RAR α
and β.
For the CETP ligand dataset [73] high lipophilicity was also accompa-
nied by high molecular weight, resulting in 91% of the ligands being in
the B-r-o-5 chemical space (i.e. two properties outside of r-o-5 limits).
However, it should be noted that this subset is small and based on pat-
ented exemplar structures rather than all discovered CETP ligands, and
there are evidence of that also less lipophilic CETP ligands can be active
Fig. 3. pH-dependent solubility and solubilisation of exemplar ligands to a range of
receptor classes. Solubility was predicted in fasted state gastric simulated intestinal ﬂuid
(FaSGSF; pH 1.6), fasted state simulated intestinal ﬂuid (FaSSIF; pH 6.5) and fed state
simulated intestinal ﬂuid (FeSSIF; pH 5.8). The fraction of compounds with a solubility
b50 μM is presented, a value that for a model compound with molecular weight of
350 Da corresponds to a concentration of 17 μg/ml. Abbraviations of targets are
provided in Box 1.
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less lipophilic ligands of CETP can be highly potent. Trieselmann et al.
synthesised a 1,1′-spiro-substituted hexahydrofuroquinoline derivative
(denoted cpd 26 in their paper) with an IC50 of 18 nM and calculated
logP of 4.6 [75]. The inhibition was highly related to the stereochemistry
and one enantiomer of cpd 26 had an IC50 of 576 nM. The authors did not
provide information on permeability, solubility or fraction absorbed but
animal studies show that the compound is as efﬁcient as anacetrapib al-
beit with a shorter half-life. These data suggest that it is possible to re-
duce lipophilicity to some extent using focused structure–activity
relationships; however, the CETP binding pocket is lipophilic and the
resulting ligands still sit within the highly lipophilic chemical space.
In addition to analyses centred on logP, a similar approach has been
undertaken for pH-dependent lipophilicity, logD, at the pH of the small
intestine (pH 6.5) and blood (pH 7.4). Whilst ligands to CETP, CB1 and
NK 1 to 3 were highly lipophilic (logD N 5) also at these pH-values,
RAR α and β had a logDpH 6.5 N 5 but a logDpH 7.4 b 5 as a consequence
of increased ionisation of acidic functional groups at higher pH. The
mean lipophilicity of ligands to CB2 and GR was just below the sug-
gested lipophilicity cut off of 5 at pH 7.4 and 6.5 (Fig. 2). In most cases,
however, the explored targets had highly lipophilic ligands even after
taking into consideration the effect of physiological pH on the ionisation
of the drug molecules.
For druggable targets wheremost ligands sit in the B-r-o-5 chemical
space, other gateways might usefully be applied for progression, rather
than those used for targets where more ligands within drug-like, rule-
of-5 chemical space are possible. In particular, lipophilic APIs often
show poor absorption, increased volume of distribution, increased
metabolic liability and increased toxicity. The relationship between
permeability and metabolic liability has allowed the development of
a modiﬁcation of the biopharmaceutics classiﬁcation system (BCS)
[76,77], that uses metabolism instead of permeability to classify com-
pounds — the biopharmaceutics drug disposition classiﬁcation system
(BDDCS). Both BCS and BDDCS use the same solubility criterion to clas-
sify compounds. The combined analysis provided by the BDDCS and BCS
is valuable to better understand drug absorption, bioavailability and
systemic disposition of these lipophilic compounds. Whilst increased
metabolic liability is likely with increasing lipophilicity, the need for li-
pophilic fragments to activate some targets makes this an inevitable
complication for such targets. Judicious choice of chemistries thatmain-
tain lipophilicity whilst reducing or redirecting metabolic pathways to
those with lower practical disadvantage will be crucial for the success
of such ligand libraries [78]. A further complication of lipophilic drug
candidates is their increased potential for toxicity [79]. The lipophilicity
efﬁciency (LipE) measure captures the intrinsic potency of a ligand at a
particular drug target, corrected for lipophilicity. LipE can be used to
identify molecules where the balance of potency versus lipophilicity is
maximised, thereby minimising downstream risk of toxicity and meta-
bolic liability [16,74,80].
7.2. Biopharmaceutical proﬁling of ligands may be used to signal food
effects
The aqueous solubility of highly lipophilic, large and ﬂexible mole-
cules, increases signiﬁcantly when bile salt concentrations rise and
when lipids are present. This reﬂects drug solubilisation within the
lipid aggregates formed by the bile components and e.g. lipid digestion
products [40,53,81]. Biorelevant dissolution media containing lipids
naturally present in the small intestine are therefore better predictors
of the solubility in vivo than assessments in pure buffers [49,82,83].
The computational approach was used to assess the potential impact
of the fasted and fed state on solubility and to evaluate how that
would inﬂuence absorption. This was undertaken to investigate
whether the target-speciﬁc compound libraries identiﬁed as having
high inherent lipophilicity were also enriched with poorly soluble com-
pounds where solubility was signiﬁcantly enhanced in the fed state —properties that are common for “grease balls”. Our hypothesis was
that predictions of large increases in solubility in FeSSIF would signal
the likelihood of a positive food effect and also the likelihood that e.g.
a lipid-based formulation would be able to efﬁciently deliver the com-
pound via the oral route.
The CBP used in silico models to predict the solubility in the fasted
and fed states of gastric and intestinal ﬂuids (Fig. 3 and Box 2) [50,84].
The intestinal ﬂuids of both states contain bile salts and phospholipids,
but with approximately ﬁve times higher concentration in the post-
prandial state. For solid state limited compounds (i.e. “brick dust”) it is
expected that the solubility in fasted and fed state would be relatively
similar since the amount of lipids is not decisive for the solubility ob-
tained [53]. Of all ligands, 40% had a predicted solubility in FaSSIF of
less than 50 μM and this proportion decreased to 16% under fed state
conditions. Interestingly, some targets had a signiﬁcantly larger
proportion of poorly soluble ligands than others. Indeed, for the
‘lipophilic targets’ most of the ligands were poorly soluble in the
fasted state, a number that dropped signiﬁcantly in the fed state. The
impact of changes in the GIT pH on solubility is also evident and exem-
pliﬁed by the acidic RAR modulators which had the lowest solubility
under gastric conditions (pH 1.6) where the compounds are in the
unionised state.
Predictions of human jejunal effective permeability (Peff) suggest
that 80% of the dataset have high intestinal permeability
(Peff N 1.0 × 10−4 cm/s), and hence, that N95% of the dose is expected
to be absorbed after oral administration provided solubility limitations
can be overcome [85]. Only 7% of the total dataset were predicted to
have low permeability (Peff b 0.2 × 10−4 cm/s). Compound series in
which molecules with poor permeability were enriched were those
targeting infections such as the macrolides and quinolones, where 45
and 47%, respectively, were predicted to have poor permeability.
These ligand series were the least lipophilic with logDpH 7.4 of 0.7 and
2.6 for quinolones andmacrolides, respectively. They also had increased
capacity to interactwithwater through hydrogen bonds, as indicated by
the large average TPSA (surface area of nitrogen, oxygen and hydrogen
bound to these heteroatoms) [32] of 127 and 186 Å2 for quinolones and
macrolides, respectively. These values should be compared to the other
targets, where amajority of the ligands (85%) had TPSAb100 Å2. A large
TPSA will also, as discussed in Section 6, reduce passive diffusion
through the cellular membranes. In two different datasets it has been
observed that when the TPSA is N140Å2 the fraction absorbed from
the intestine can be expected to be b10% [30,86].
The CBP is based on a variant of the BCS [76], herein adjusted to
match analyses performed in the drug discovery setting (Box 2). The
BCS is traditionally used to signal the need for bioequivalence studies
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classes deﬁned on the basis of solubility and permeability properties.
BCS class 1 compounds have high solubility and high permeability;
they are expected to have high absorption regardless of the physiologi-
cal conditions and/or the dosage form administered. BCS class 2 com-
pounds have low solubility/high permeability and are expected to
show solubility and/or dissolution limited absorption, and therefore
the amount that is absorbed becomes highly dependent on the formula-
tion. BCS class 3 and 4 compounds have high solubility/low permeabil-
ity and low solubility/lowpermeability, respectively. The applicability of
the BCS is limited in the discovery setting since it relies on the knowl-
edge of the oral dose to classify solubility. In the discovery setting this
information is usually not available and the CBP was therefore based
on predicted solubility valueswithout dose adjustment (formore infor-
mation, see Box 2).
The CBP predicted that compound series directed to targets with li-
gands with average lipophilicity (logP 2–3) would bemainly positioned
in BCS class 1 region, where solubility and permeability are high, consis-
tent with complete absorption (Fig. 4). Exemplar targets predicted to be
compatible with BCS Class 1 ligands include 5-hydroxytryptamine sub-
type 2c (5-HT2) and melatonin receptors (MT) 1 and 2, with 70% and
51% of molecules, respectively, predicted to belong to this class. Indeed,
MT1 agonists in the series investigated here have shown almost com-
plete absorption (N84%) [87,88]; however oral bioavailability is typical-
ly limited by extensive ﬁrst pass hepatic metabolism. Ligands to the
non-lipophilic targets (e.g. the quinolone-based antibiotics) are mainly
permeability-limited with 77% of the compounds predicted to have
permeability-limited absorption (classical BCS Class 3). Although it
proved difﬁcult to ﬁnd permeability data for recently discovered
quinolone-based antibiotics, reference quinolones such as ciproﬂoxacin,
levoﬂoxacin andDK-507a (a predecessor to analogues used as exemplar
structures) are known to have poor membrane permeability [51]. For
the non-lipophilic targets, the impact of the post prandial state on
drug solubilisation wasminor and hence, the biopharmaceutical proﬁle
of ligands to these targets was similar for the solubility predictions of
the pre- and post-prandial states. In contrast, ligands of ‘lipophilic tar-
gets’ showed signiﬁcantly different biopharmaceutical proﬁles. TwoFig. 4. Computational biopharmaceutical proﬁling (CBP). The position of the ligand series in a di
of solubility versus permeability. The cut-off values used for solubility were: poorly soluble b50
were used for permeability: high permeability N 1.0 × 10−4 cm/s; low permeability 0.2 × 10−4
compounds belonging to this part of the CBP. BCS class 1-like compounds are positioned in the
BCS 3-like in the upper left (yellow) corner and BCS 4-like in the lower left (red) corner. The
proﬁles. The other panels show that ligands for 5HT2c are mostly BCS class 1, CETP inhibitors asuch targets are shown in Fig. 5. A majority of the compounds directed
towards these targets are BCS class 2-like compounds and for most of
them, absorption is predicted to be solubility-limited. For these targets,
andmany others, the solubility increased in the fed condition. As exam-
ples, the fraction of BCS class 2 RAR ligands and γ-secretase inhibitors
was reduced from 0.74 to 0.50 in the fasted state to 0.31 and 0.10 in
the fed state, respectively. Hence, the positive solubilising effect of nat-
urally available lipids pushedmany of these compounds to become BCS
class 1-like.
7.3. Biopharmaceutical proﬁling of ligands signals need for enabling
formulations
The CBP facilitates early identiﬁcation of targets for which non-
traditional decision gateways might be required during drug discovery,
and for which non-traditional formulation approaches are likely
demanded for successful clinical development. The CBPwas used to an-
alyse the requirements of the target rather than the properties of the
drug molecule. This approach provided a holistic view of differences in
the required physicochemical properties of drug candidates across a
range of different target biologies. Targets where a majority of the li-
gands fall within the lower, right quadrant of the CBP proﬁle (see the
graphs presented in Figs. 4 and 5) are likely to require atypical develop-
ment strategies since current evidence suggests that the identiﬁcation
of water soluble drug candidates, that retain sufﬁcient potency, is un-
likely. The fed state CBP also provides information on compounds
where solubility is likely to increase when higher concentrations of gas-
trointestinal amphiphiles (e.g., bile salts and phospholipids) are present
and hence signals that solubilising formulations such as lipid-based for-
mulations [89], are likely to result in increased, more reproducible and
more reliable absorption. This is consistent, for example, with recently
published studies showing enhanced exposure of inhibitors of the
lipophilic target CETP after administration in lipid-based formulations
[90,91]. Further evidence of the utility and accuracy of the CBP comes
from a retrospective analysis of formulations used for different
targets. For example, a number of conventional tablets are used for de-
livery of marketed for 5-HT2c modulators (e.g., marketed products ofscovery directed variant of the BCS (Box 2). Compoundswere classiﬁed into a 3 × 3matrix
μM; highly soluble N200 μM; intermediate in between these values. The following values
cm/s; intermediate in between these values. The larger the circle the larger the fraction of
upper right (green) corner, BCS class 2-like compounds in the lower right (yellow) corner,
upper left panel shows the distribution of all 1620 ligands without identifying the target
re almost entirely BCS Class 2 and macrolides are largely BCS class 3.
Fig. 5. Impact of lipids present in fed state intestinal content on apparent BCS classiﬁcation based on computational biopharmaceutical proﬁling. The position of the ligand series in a
discovery directed variant of the BCS (Box 2). Compounds were classiﬁed into a 3 × 3 matrix of solubility versus permeability. The cut-off values used for solubility were: poorly
soluble b50 μM; highly soluble N200 μM; intermediate in between these values. The following values were used for permeability: high permeability N 1.0 × 10−4 cm/s; low
permeability 0.2 × 10−4 cm/s; intermediate in between these values. The larger the circle, the larger the fraction of compounds belonging to this part of the CBP. BCS class 1-like
compounds are positioned in the upper right (green) corner, BCS class 2-like compounds in the lower right (yellow) corner, BCS 3-like in the upper left (yellow) corner and BCS 4-like
in the lower left (red) corner. For both CETP inhibitors (top panels) and γ-secretase inhibitors (bottom panels) the majority of ligands are expected to be highly permeable but have
low solubility in fasted intestinal ﬂuid (left hand panels). In contrast in both cases, solubility in fed intestinal ﬂuids is signiﬁcantly higher — i.e. a shift towards the green quadrant. This
suggests that enabling formulation such as lipid-based formulations may be beneﬁcial for drug delivery for these receptor classes.
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CBP to belong to the BCS Class 1 group and therefore not in need of an
enabling formulation. In contrast, the γ-secretase inhibitors, identiﬁed
as being BCS Class 2-like with improved solubility in FeSSIF, have been
explored in animal models with cosolvents and surfactants (e.g. 80%
PEG400 [92] and mixtures of 10% dimethylformamide and 30% propyl-
ene glycol [93]). Thus the CBP had accurately signalled the need for an
enabling formulation, e.g. lipid-based, in order to achieve acceptable
plasma concentrations.
There are at least two ramiﬁcations of the CBP. First, it provides data
to support a re-examination of the typical pharmaceutical decision-
gates for compound progression for some targets (for example relaxing
the desire for drugs to have logPs of less than 5). Second, it can signal a
likely requirement for a solubility enhancing formulation early in the
development cycle. This is an important distinction. Lead optimisation
strategies that are re-focused on the identiﬁcation of drug candidates
with physicochemical properties optimised for a particular formulation
approach will be quite different to those that adopt traditional lead op-
timisation strategies that attempt to promote aqueous solubility. For
traditional drug-like targets, decision gateways based on historical pro-
gression criteria (e.g., molecular weight, number of rotatable bonds,
PSA) provide a useful early indicator of the ADMET proﬁle. In contrast,
the CBP suggests that rigid application of these criteria is unlikely to
be successful for targets with ligands located in the B-r-o-5 and the
lower right corner of the graphs displayed in Figs. 4 and 5 (classical
BCS class 2). It is also worth noting that the application of rules such
as the r-o-5 seems to have driven the discovery process towards the
borders of the decision gates, with the end result of the lead optimisa-
tion process being compounds with molecular properties that are just
slightly below the cut-off values given for these gateways [16]. In the
dataset explored herein, ~7–10% of all the molecules had molecularproperties ‘just below’ the margin of the rule-of-5 (e.g., 9 % had molec-
ular weights of 470–500 Da and 7% had a logP of 4.7–5). Whilst these
compounds are indeed ‘drug-like’ based on rigid application of decision
gateways, such ‘close to B-r-o-5 space’ compounds are likely to remain
challenging to develop.
8. In silico prediction to support selection of formulation strategy:
amorphisation vs lipid-based formulations
Selection of an appropriate enabling formulation strategy is still
based mainly on results obtained from experimental screening assays
[94–96]. Indeed, the properties of the API are often largely ignored
when choosing the most appropriate strategy and a large number of
standard formulations are simply tested in a somewhat technology-
agnostic fashion. To some extent the selection of which formulation
strategy to pursue seems to be based on previous experience, i.e., if a
formulator has a backgroundwith cyclodextrins or lipid-based formula-
tions (LBFs) then these excipients are likely amongst the ﬁrst to be ex-
plored whereas another formulator with experience of amorphisation
may use this as a ﬁrst ‘go-to’ strategy. There is signiﬁcant potential
therefore, to better inform these decisions if knowledge-based compu-
tational tools can be developed to forecast ideal formulation strategies
based on the molecular structure of the drug. In the sections below
the ﬁrst steps towards computational tools that allow prediction of
themolecular properties that predispose to the utility of amorphisation,
as ameans to address solid-state limited solubility, and LBFs, as ameans
to address solvation-limited compounds, are described. The in silico
methods currently available for assessment of ‘formulate-ability’, i.e.
models predictingwhich enabling formulation tomatchwith a particu-
lar API, typically apply multivariate data analyses and Molecular
Dynamics (MD) simulations. Performance of formulations can be
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STELLA and examples of recent computer-guided LBF performance
analyses are provided by O'Shea et al. [97], Fei et al. [98] and Zheng
et al. [99]. It should be noted that often a certain amount of in vitro
data is needed as input for these simulations to be accurate and that en-
tirely in silico approaches remain out of reach.
8.1. Amorphous formulations
Amorphous formulations are used to diminish the impact of the
solid-state on dissolution and solubility. In the amorphous state no
long range order remains and the intermolecular interactions in the
solid form are therefore weaker than those in the crystalline form. A
number of process technologies can be used to produce the amorphous
material, the most common being rapid evaporation of solvents (spray-
drying), freeze-drying, increased temperature (melt extrusion, melt
quenching), anti-solvent precipitation and mechanical activation
[100]. The idea behind using amorphous material for drug delivery is
that the amorphous solubility is typically much higher than the crystal-
line solubility and hence, a supersaturated solution is easier to obtain
from the amorphous form. This increase in concentration is then direct-
ly related to an increase in ﬂux across the intestinal wall since in a
supersaturated solution the molecules exist as monomers [101]. Amor-
phous materials and supersaturated solutions are both unstable; poly-
mers are therefore used in the formulations to improve product
stability and the stability of the supersaturated solutions formed on dis-
solution by hindering nucleation and crystal growth. As soon as crystal
growth starts, the solubility enhancing effect is lost since the material
then re-attains the properties of the crystalline material.
The rate of nucleation and crystal growth in the formulation is affect-
ed by the dynamics, i.e., molecular mobility, of the amorphous phase.
The transformation from the amorphous to the crystalline form is driv-
en by thermodynamics; the crystalline form is the energetically
favourable and hence, more stable form. However, the nucleation and
crystallisation are results of kinetic barriers that have to be overcome,
and different conditions may therefore result in different times for nu-
cleation (induction time). A detailed analysis on the thermodynamic
and kinetic aspects of nucleation and crystal growth is provided by Tay-
lor and Zhang [102]. The glass stability is often determined bymeasure-
ment of the rate at which the amorphous material is transformed into
its crystalline counterpart and the glass transition temperature (Tg)
has been used to indicate glass stability. However, there are also reports
of alterations in amorphous state properties and stability as a function of
changes to productionmethodswithout any signiﬁcant alterations in Tg
[103,104]. On the other hand, Tg has beenused to deﬁne suitable storage
temperatures and is able to identify drugs for which amorphous formu-
lations are unlikely to be stabilised [105]. Computational tools that can
predict Tg are therefore warranted, and recently the ﬁrst attempts to
achieve in silico prediction of Tg were published [106]. The resulting
SVR model predicted the test set (n = 24) with an RMSE of 18.7 K. In
other words, the Tg could be predicted with greater accuracy than Tm
(discussed in Section 4.1). The important molecular descriptors for Tg
were related to the number of hydrogen bonds, the number of ring
structures and the maximum sigma Fukui index. Whilst hydrogen
bonds and number of rings are easily understandable the sigma Fukui
index may be a more difﬁcult descriptor to understand. Hydrogen
bonds have been shown to be a positive factor for good glass-forming
ability [107], whereas ring structures have been related, amongst
others, to the ease by which a compound can order itself in a dense
packing structure in the crystal [52,108]. The sigma Fukui index pro-
vides information on local reactivity of sigma electrons in themolecule,
and can be further decomposed into nucleophilicity and electrophilicity
of the molecule [109].
Glass-formation, i.e., the ability of an API to exist in its amorphous
state (using relatively standardised production technologies and assess-
ment of amorphous content at room temperature) is related tohydrogen bonding capacity,molecular volume, and number of rotatable
bonds [110–112]. The usefulness of these and other calculated molecu-
lar properties to predict glass-forming ability and glass stability has
been explored [52,113–115]. The ﬁrst attempt to predict the glass-
forming ability was based on a dataset of 32 compounds. This dataset
showed that molecular descriptors related to aromaticity, symmetry,
distribution of electronegative atoms, branching of the carbon skeleton
and molecular size could be used to accurately sort compounds into
glass-formers and non-glass-formers [52]. The properties reﬂect, to
some extent, the conﬁgurational entropy (branching of carbon skeleton
and molecular size). This property favours glass formation. When a
large number of conformers interact with each other, the chances in-
crease that such molecules “lock in” solid states other than the stable
polymorph. Aromaticity (described by the number of benzene rings)
and symmetry also impose directionality in the interaction between
molecules; these two factors hinder glass formation. These aromatic
features will drive solid state interactions through strong van der
Waals interactions as a result of π–π stacking and therefore favour crys-
tallinity. Symmetry, similarly, creates handles between themolecules in
their interaction and gives direction to how compounds interact and
form intermolecular bonds, again favouring crystallinity. Finally, well
distributed electronegative atoms appear to be favourable for glass-
forming ability. This may, in part, be because some of these atoms
(in particular, nitrogens and oxygens) form hydrogen bonds, an
established factor in glass formation. If these atoms are well distributed
over themolecule, themolecule has several anchor points for hydrogen
bond formation. Based on larger datasets (n= 50 and 131) it is evident
that molecular weight (Mw) can be used to provide an early indication
of glass-forming ability [113,114]. As a rule of thumb, good glass-
formers have a MwN300 whereas compounds with Mwb200 remain
in their crystalline form, regardless of production technology. For
compounds with Mw between 200 and 300, a molecular descriptor
reﬂecting both the size and shape of the molecule has been shown to
differentiate glass-formers and non-glass-formers (crystallinematerial)
[95].
WhilstMwandmolecular descriptors that carry information regard-
ing both size and shape can indicate compounds that can be readily
transformed into the amorphous state, they do not provide information
of the stability of the amorphous material. In an attempt to identify the
properties that dictate stability, a dataset of 77 compounds containing
both stable and non-stable glass-formers, was used to extract the mo-
lecular properties that correlate with stability (or instability) [113].
For this dataset two descriptors were predictive for stability; the num-
ber of hydrogen bond acceptors and the absolute values of Hückel pi
atomic charges for C atoms. In another recent study, hydrogen bond ca-
pacity and size were the two most important calculated descriptors
[116]. These predictions seem to accurately capture important molecu-
lar properties for glass stability since the number of hydrogen bond
acceptors has also been identiﬁed in laboratory experiments on amor-
phous stability [117]. It should be noted that whilst Mw alone describes
glass-forming ability with 86% accuracy, amorphous stability is some-
what less accurately predicted (training and validation datasets were
78% and 69% correctly classiﬁed, respectively) [113]. Hence, stability
seemsmore difﬁcult to predict than glass-forming ability. This is expect-
ed since the glass-forming ability only identiﬁes whether the material
can form a glass or not, i.e. the potential to “lock in” a solid state struc-
ture other than that obtained in a crystalline material with long range
order. In contrast, stability models also have to capture the mobility of
the amorphous form. Most importantly, the computational models
have contributed to the molecular understanding of amorphous
materials (Fig. 6).
However, the API has to be formulated with stabilising excipients to
achieve the positive effects of amorphisation and improve drug deliv-
ery. Theoretical analyses of e.g. polymer–drug interaction, miscibility
of excipients and solvents have historically been performed making
use of the Flory Huggins equation or the Hansen Solubility Parameters
Fig. 6. Computational prediction of glass-forming ability and physical stability from
molecular structure of the drug. Computational models obtained using multivariate data
analysis are accurately sorting compounds into glass-formers and non-glass-formers
based on molecular descriptors as only input [52,113,114]. Typical properties of
importance for amorphisation are molecular size and intermolecular hydrogen bond
capacity, both of which are positive for the production of an amorphous material.
Rigidity, aromaticity and number of benzene rings are strongly related to the formation
of a stable crystal lattice; these properties drive crystallisation. Glass-formers can
thereafter be further studied with regard to their tendency to crystallise in the solid
form and computational models are available for the prediction of physical (dry)
stability [113,114]. To our knowledge no computational models exist that can predict
stability of amorphous materials exposed to water. This property is of utmost
importance for compound performance after oral administration and therefore,
computational models predicting this property are actively sought. Current strategies to
arrive at such models are making use of MD simulations (see e.g. [120–123]).
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tential use in such analysis. MD simulations study the physical move-
ments of atoms and molecules, and dependent on the resolution scale
applied, can be used to study movements (folding, diffusion, aggrega-
tion etc.) of large molecules in complex, multicomponent systems. MD
simulations arewell-established in biophysics, e.g. for studies of cellular
membranes and proteins, and has recently been introduced as a tool to
better understand formulation and dosage form design. In the ﬁeld of
amorphous drug formulations MD has been used to investigate molec-
ular interactions between the API and stabilising polymers typically
used in amorphous solid dispersion (ASD) [120–123]. Xiang and Ander-
son have published a series of papers in which they explore molecular
interactions in relatively complex systems. Recently, they explored
indomethacin together with the commonly used polymer HPMCAS to
investigate the interactions between such ASDs and water. The simula-
tions were performed in the presence of water (0.7–13.2 %w/w) to bet-
ter understand processes occurring as a result of water being adsorbed
by the polymer during storage or processes involved during release to
awater-based environment. TheMD simulationswere used to calculate
the density and the Tg and both these were in good agreement with
experimental data. At a macroscopic level it could also be observed
that the water molecules were isolated at low water content but
formed clusters or strands at high concentrations. The water acted as
plasticisers resulting in increasing polymer mobility andwater diffusiv-
ity at higher water content. The movement of the water in the polymer
was ‘hopping’ at low concentrations whereas at higher concentrations
water molecules were found to move fast within the water clustersbut slowly diffused through the polymer matrix [122]. Xiang and
Anderson have performed similar studies for other pharmaceutical
polymers, andhave been successful in simulating the density,water sorp-
tion isotherm and Tg of poly(lactide) (PLA) as well as molecular interac-
tion and miscibility between indomethacin and polyvinylpyrrolidone
(PVP) [121,124]. These studies are examples of ongoing computational
efforts to explore complex processes that take place in formulations.
To summarise, it has during the last years become evident that com-
putational simulation methodologies are available that may inform us
on formulation performance of amorphous products during storage
and during dissolution and release in vivo. In the not too distant future,
decisions on whether or not to pursue amorphous formulations for a
particular API may therefore be computationally-informed at several
levels. We foresee the following scenario: a rule-based system based
on easily and rapidly calculated molecular properties to determine
whether the API is a glass-former and if so, whether it will suffer from
stability issues. This is followed by MD simulations of the API together
with a number of polymers using differentmechanisms for stabilisation,
and lead polymers are identiﬁed in silico. Initial experimental trials of
ASD formulations may thereafter be attempted with drugs that have
been proven suitable for the technology and with the excipients that
are most likely to promote physical stability and maintain supersatura-
tion once the dosage form is dissolved.8.2. Lipid-based formulations
LBFs are mixtures of lipids, surfactants and/or cosolvents, and are
commonly employed to enhance the oral bioavailability of poorly
water-soluble lipophilic drugs. This is achieved ﬁrstly by overcoming
traditional solid–liquid dissolution limitations to absorption (since the
drug is typically predissolved in the formulation) and secondly by pro-
viding lipids and surfactants that boost the solubilisation capacity of
the GIT. For a more detailed review of LBF development, performance
and utility, the reader is referred to Feeney et al. in this theme
issue [125]. Although LBF suspensions are possible and have been
commercialised, lipid solution formulations are preferred since they
simplify manufacture and accurate capsule ﬁling, and often lead to
less variable in vivo performance. An important condition for successful
use of an LBF is therefore that the drug dose can be adequately dissolved
in the lipid system used [7,126]. In silico prediction of lipid solubility
is therefore a key goal to enhance the speed and utility of LBF
development.
Recent studies of lipid systems have used the log-linear model [127,
128], or related models [129–131] to estimate drug solubility in com-
plex lipidmixtures. The log-linearmodel is based on studies ofmixtures
of water and cosolvents. This methodology, and its variants, requires
experimental solubility measurements and hence, a large amount of
compound needs to be synthesised. The experiments are also time con-
suming, relatively labour intensive and only of medium through-put.
Computational prediction of drug solubility in commonly used excipi-
ents, or in the LBF itself, would therefore be beneﬁcial and can be
expected to increase the throughput and lower the costs of LBF develop-
ment. Multivariate data analysis was recently employed to develop
models that could predict drug solubility in single excipients [56,132].
The dataset consisted of ~40 structurally diverse compounds deter-
mined in nine key LBF excipients. This dataset indicates that computa-
tionally predicted solubility values obtained from PLS models of each
excipient can successfully predict loading capacity of complex LBFs
(Fig. 7). To arrive at the ﬁnal loading in the more complex LBF, the pre-
dicted solubility in each excipient is summed after correcting for the
weight fraction of each excipient [132]. The molecular descriptors
found to be detrimental to good solubility in glyceride lipids are the
numbers of nitrogens and conjugated double bonds [56]. The latter
partly reﬂects rigidity and aromaticity. Common features for com-
pounds that have high lipid solubility are that they are neutral or
Fig. 7. Computational prediction of drug loading in lipid-based formulations (LBFs).
Recently the ﬁrst attempts to predict solubility in excipients commonly used in LBFs
have been published [56,132]. Whilst it has proven possible to predict solubility in
glycerides from molecular structure alone, knowledge of the melting point and entropy
of fusion improve these models. More importantly, they are required to produce
accurate models for ethoxylated surfactants and cosolvents. Important properties
driving solubility in lipids are low polar surface area and low melting point. Non-
protolytes and weak bases seem to be better solvated by the excipients than acidic
compounds. When solubility values have been predicted in the excipients (SPred Excip),
the loading capacity in any new LBF can be calculated by summing the contribution of
each excipient (solubility corrected for the weight fraction, WExcip). Hence, the potential
utility of a LBF strategy (at least in terms of potential drug dose) for a particular
compound can be assessed early in development using computational approaches alone.
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PSA and a Tmb150 °C [132].
MD simulations have also been used to study internal structure of
LBFs upon dilution in water, largely to better understand the solvation
capacity of these formulations when administered with a glass of
water [7,133–137]. In a recent study the liquid phase behaviour of sodi-
um oleate, sodium laurate andwater was explored to better understand
colloidal interactions [133]. The complete ternary phase diagram was
reproduced in silico and the simulations identiﬁed the three phases
(micellar, hexagonal, lamellar) found experimentally. This study
shows that MD simulations of systems including naturally available
lipids and excipients found within LBFs are feasible and produce accu-
rate structures. A remaining challenge is to perform these simulations
in solvents mimicking the fasted and fed intestinal ﬂuids, in which nat-
urally available surfactants (bile salts) and phospholipids inﬂuence the
formation of nanoaggregates. The intestinal ﬂuid is also dynamic and
its solvation capacity changes in response to dilution, digestion, and
absorption. When computational simulations can capture such
dynamic changes, the intra- and interindividual variability in solvation
capacity and the performance of the LBFs may be possible to predict
computationally.9. Conclusion
This work highlights the potential utility of computer-based
methods to identify likely formulation options in early drug develop-
ment. These methods can also be applied to bridge the drug discovery
and early development settings and are applicable at several different
levels. These include early identiﬁcation of the likelihood of solubility-
limited absorption and potential food effects, as well as a better under-
standing of the molecular determinants of low solubility. Further they
can be used to indicate prospective formulation-dependence of drugs
aimed at particular drug targets. Finally, computational methods have
the potential to identify the most appropriate formulation approach
based on the molecular properties of the drug. These computational
approaches will accelerate knowledge-based decision making for drug
delivery and formulation science and speed dose form optimisation
for a particular API. The computational biopharmaceutical proﬁling
tool enables the inﬂuence of target biology on potential drug delivery
strategies to be assessed very early in the discovery cycle. This informa-
tion will help guide project teams during the early target identiﬁcation
and lead optimisation process. This type of computational analysis only
requires information calculated from the molecular structure of the li-
gands and therefore has the potential to provide a virtual signal of the
need for adoption of enabling formulation strategies. Early recognition
of this need has the potential to inﬂuence adoption of non-traditional
(but possibly more appropriate) decision pathways as the project pro-
gresses. This in turn is of importance for successful development of
the highly lipophilic ligands for B-r-o-5 targets that are the current
focus of many discovery programmes.
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